European Medicines Agency
Evaluation of Medicines for Human Use

Doc.Ref.: EMEA/CHMP/465199/2008

ASSESSMENT REPORT

FOR

Zomarist

International Nonproprietary Name: vildagliptin / metformin hydrochloride

Procedure No. EMEA/H/C/001049

Assessment Report as adopted by the CHMP with
all information of a commercially confidential nature deleted.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

TABLE OF CONTENTS

1. BACKGROUND INFORMATION ON THE PROCEDURE

1.1 Submission of the dossier

The applicant Novartis Europharm Ltd. submitted on 4 July 2008 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for Zomarist, through the centralised procedure according to Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 24 April 2008.

The legal basis for this application refers to Article 10c of Directive 2001/83/EC, as amended – relating to informed consent from the marketing authorisation holder Novartis Europharm Ltd. for the authorised medicinal product Eucreas (EU/1/07/425/001–018).

Licensing status:
The initial product, Eucreas, has been given a Community Marketing Authorisation on 14 November 2007.

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:
Rapporteur: **Bengt Ljungberg** Co-Rapporteur: **Pierre Demolis**

1.2 Steps taken for the assessment of the product

- The application was received by the EMEA on 4 July 2008.
- The procedure started on 27 July 2008.
- The Rapporteur's Assessment Report was circulated to all CHMP members on 29 August 2008. The Co-Rapporteur's Assessment Report was circulated to all CHMP members on 29 August 2008.
- During the meeting on 22-25 September 2008, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Zomarist on 25 September 2008.

2. SCIENTIFIC DISCUSSION

2.1 Introduction

This application has been submitted as an informed consent application in accordance with Article 10c of Directive 2001/83/EC as amended.
Therefore, consent from the MAH of the Eucreas application, which had been submitted as a full application under Art 8(3) of Directive 2001/83/EC as amended, has been given allowing access to Module 2 to Module 5 of the initial dossier of this authorised product and any subsequent post-marketing procedures submitted, assessed and approved. The application for Zomarist consists only of Module 1 information.

As a consequence, quality, safety and efficacy of the Zomarist medicinal product are identical to the up-to-date quality, safety and efficacy profile of Eucreas. Information on the scientific discussions can be found in the Eucreas CHMP assessment report and in the European Public Assessment Report (EPAR).

Vildagliptin belongs to a new class of oral anti-diabetic drugs and is a selective and reversible inhibitor of dipeptidyl peptidase 4 (DPP-4), the enzyme which inactivates the incretin hormones, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP), hormones which significantly contribute to the maintenance of glucose homeostasis.
Metformin is an established first line treatment for type 2 diabetes mellitus, acting primarily to enhance hepatic and peripheral insulin sensitivity.
Vildagliptin and metformin is intended for use in patients with T2DM as fixed combination tablets.

The approved indication is:

“Zomarist is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.”

The tablets are available in 2 strengths: vildagliptin 50 mg and metformin 850 mg, and vildagliptin 50 mg and metformin 1000 mg. In all cases, the recommended daily dose is 100 mg vildagliptin, allowing a daily dose of 1700 to 2000 mg metformin.

2.2 Quality aspects

Since this application is an informed consent of the Eucreas application, the quality data in support of the Zomarist application are identical to the up-to-date quality data of the Eucreas dossier which have been assessed and approved (including all post-marketing procedures).

2.3 Non-clinical aspects

Since this application is an informed consent of the Eucreas application, the non-clinical data in support of the Zomarist application are identical to the up-to-date non-clinical data of the Eucreas dossier, which have been assessed and approved (including all post-marketing procedures).

2.4 Clinical aspects

Since this application is an informed consent of the Eucreas application, the clinical data in support of the Zomarist application are identical to the up-to-date clinical data of the Eucreas dossier, which have been assessed and approved (including all post-marketing procedures).

2.5 Pharmacovigilance

Detailed description of the Pharmacovigilance system

The CHMP considered that the Pharmacovigilance system as described by the applicant fulfils the legislative requirements.

Risk Management Plan

The CHMP did not require the MAA to submit a risk management plan because the reference product Eucreas does not have additional risk minimisation activities beyond providing guidance in the prescribing information.

2.6 Overall conclusions, risk/benefit assessment and recommendation

Since this application is an informed consent of the Eucreas application, the CHMP considered that the risk-benefit balance of Zomarist was favourable and therefore recommended the granting of the marketing authorisation for the following indication:

“Zomarist is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.”